Supplemental Information

circPHIP promotes oral squamous cell carcinoma progression by sponging miR-142-5p and regulating PHIP and ACTN4 expression

Wen Su, Yuehong Shen, Yufan Wang, Feng Wang, Xia Hong, Yuling Chen, Yuntao Lin, and Hongyu Yang
Supplementary Figure 1

**Supplementary Figure 1** Bioinformatics analysis of the correlation between PHIP and ACTN4 expression in head and neck tumors.
Supplementary Figure 2

Supplementary Figure 2 a, b TCGA database analysis of the relationship between ACTN4 (a) or PHIP (b) expression and patient prognosis and HPV infection.
Supplementary Table 1 Correlation between clinicopathological features of patients with OSCC and circPHIP expression.

| Parameter                        | No. of patients | Mean ± SEM | P value |
|----------------------------------|-----------------|------------|---------|
| **Gender**                       |                 |            |         |
| Male                             | 38              | 11.38 ± 0.3444 | 0.8716 |
| Female                           | 24              | 11.30 ± 0.3132 |         |
| **Age (yr)**                     |                 |            |         |
| <60                              | 25              | 11.66 ± 0.3292 | 0.3008 |
| ≥60                              | 37              | 11.14 ± 0.3379 |         |
| **Tumor size (cm)**              |                 |            |         |
| <5                               | 52              | 11.35 ± 0.2633 | 0.9881 |
| ≥5                               | 10              | 11.34 ± 0.6427 |         |
| **Differentiation grade**        |                 |            |         |
| Well-moderate                    | 40              | 11.60 ± 0.3184 | 0.1657 |
| Poor-undifferentiated            | 22              | 10.89 ± 0.3476 |         |
| **Lymph node status**            |                 |            |         |
| Negative                         | 29              | 10.73 ± 0.3649 | 0.0149*|
| Positive                         | 33              | 11.89 ± 0.2951 |         |
| **TNM stage**                    |                 |            |         |
| I-II                             | 36              | 10.74 ± 0.3108 | 0.0023**|
| III-IV                           | 26              | 12.19 ± 0.3218 |         |
| **HPV stage**                    |                 |            |         |
| Negative                         | 48              | 10.98 ± 0.2669 | 0.0037**|
| Positive                         | 14              | 12.62 ± 0.4139 |         |